Valneva SE (VALN) Total Non-Current Liabilities (2020 - 2026)

Valneva SE (VALN) posted Total Non-Current Liabilities of $235.4 million for Q1 2026, up 1.46% sequentially from $232.0 million in Q4 2025, and up 11.47% YoY from $211.2 million in Q1 2025.

Valneva SE (VALN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Valneva SE has reported Total Non-Current Liabilities for 7 years, with the latest figure at $235.4 million in Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 11.47% year-over-year to $235.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $235.4 million (up 11.47% YoY) and the FY2025 annual result came in at $232.0 million, up 4.99% from the prior year.
  • Total Non-Current Liabilities improved to $235.4 million in Q1 2026 per VALN's latest filing, from $232.0 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $298.6 million in Q1 2022 and troughed at $120.7 million in Q2 2023.
  • A 5-year average of $192.7 million and a median of $208.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities tumbled 60.14% in 2022, then jumped 76.52% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $126.7 million in 2022, then jumped by 46.91% to $186.1 million in 2023, then gained by 17.26% to $218.2 million in 2024, then advanced by 6.34% to $232.0 million in 2025, then rose by 1.46% to $235.4 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $235.4 million, $232.0 million, and $172.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 40.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 1.53 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.88 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.32 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.20 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.17 Bn
10 Valneva SE 618.67 Mn 477.41 Mn 1.86 Mn 236.92 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 236.92 Mn
Mar 31, 2026 235.43 Mn
Dec 31, 2025 232.03 Mn
Sep 30, 2025 172.17 Mn
Jun 30, 2025 181.72 Mn
Mar 31, 2025 211.21 Mn
Dec 31, 2024 218.21 Mn
Sep 30, 2024 208.65 Mn
Jun 30, 2024 213.01 Mn
Mar 31, 2024 214.57 Mn
Dec 31, 2023 186.09 Mn
Sep 30, 2023 157.70 Mn
Jun 30, 2023 120.68 Mn
Mar 31, 2023 130.90 Mn
Dec 31, 2022 126.67 Mn
Sep 30, 2022 160.20 Mn
Jun 30, 2022 208.85 Mn
Mar 31, 2022 298.60 Mn
Dec 31, 2021 317.78 Mn
Dec 31, 2020 233.54 Mn